TCON - Tracon's TRC102 an Orphan Drug in U.S. for malignant glioma

The FDA has granted Orphan Drug designation to TRACON Pharmaceuticals' (TCON) TRC102 for the treatment of patients with malignant glioma, including glioblastoma ((GBM)).Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.TRC102 is a small molecule inhibitor of the DNA base excision repair pathway, that causes resistance to alkylating and antimetabolite chemotherapeutics.Shares are up 3% premarket.

For further details see:

Tracon's TRC102 an Orphan Drug in U.S. for malignant glioma